SOX13 is a group D SRY-box transcription factor that binds DNA at the consensus sequence 5'-AACAAT-3' 1 and functions as a key cell fate modulator across multiple lineages 2. In immune development, SOX13 modulates T cell specification, particularly gamma-delta T cell differentiation and IL-17A production, through interactions with TCF7/TCF1 3. SOX13 acts as a Wnt signaling inhibitor 4, though it can also promote canonical Wnt signaling when regulated by POU3F2 in neural progenitors 5. In neural development, SOX13 regulates oligodendrocyte differentiation through MPZ and MBP promoter binding 6. Clinically, SOX13 demonstrates significant disease relevance. Truncating de novo variants in SOX13 are associated with congenital anomalies of the kidney and urinary tract (CAKUT) 7. In cancer, SOX13 expression is elevated in gastric and breast cancers, correlating with poor prognosis and therapeutic resistance [PMID:38769295; 87]. In hepatocellular carcinoma, SOX13 promotes metastasis by transcriptionally activating Twist1 9. Notably, targeting SOX13 with zanamivir overcomes ferroptosis resistance in gastric cancer by disrupting electron transport chain supercomplex assembly 10. These findings establish SOX13 as both a developmental regulator and potential therapeutic target in human disease.